Rather unsurprising finding at this point, but valuable nonetheless Per usual, joint efficacy for bimekizumab (IL17i) ~
Tweet Content
Rather unsurprising finding at this point, but valuable nonetheless
Per usual, joint efficacy for bimekizumab (IL17i) ~similar to TNF
New twist; similar loss in efficacy over time. Nice to have another IL17i; not sure this is a "blockbuster"
@RheumNow #ACR23 Abstr1437 https://t.co/4sVfSz7ZnK
Show on Archive Page
On
Display in Search Results
On
PDQ
Off